What Happened?
Shares of genetic testing company Natera (NASDAQ: NTRA). fell 12.2% in the afternoon session after the company reported mixed first-quarter 2026 financial results, where strong revenue growth was overshadowed by a wider-than-expected net loss.
Although Natera posted a significant 38.8% year-over-year increase in revenue to $696.6 million, beating analysts' expectations, investors focused on the deteriorating bottom line. The company's GAAP loss widened to $0.60 per share from $0.50 per share in the same quarter last year. This result also missed Wall Street's consensus estimate of a $0.55 loss per share. The widening loss, despite surging sales, raised concerns among investors about the company's path to profitability.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Natera? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Natera’s shares are quite volatile and have had 15 moves greater than 5% over the last year. But moves this big are rare even for Natera and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 21 days ago when the stock gained 5.4% on the news that the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy costs.
For healthcare providers and medical device manufacturers, lower oil prices directly reduce the cost of operating large hospital facilities and shipping sensitive medical equipment. This margin relief is vital for a sector that has been squeezed by high transportation overhead, allowing for a more favorable outlook on quarterly earnings. The "risk-on" sentiment sparked by the ceasefire is also driving capital back into high-growth biotech and pharmaceutical names.
As broader market volatility recedes, investors are more willing to fund long-term R&D and clinical trials that were previously shadowed by macroeconomic uncertainty. The stabilization of the global economy ensures that both elective procedures and pharmaceutical demand remain on a steady upward trajectory for the remainder of 2026.
Natera is down 13.6% since the beginning of the year, and at $197.64 per share, it is trading 22.3% below its 52-week high of $254.40 from January 2026. Despite the year-to-date decline, investors who bought $1,000 worth of Natera’s shares 5 years ago would now be looking at an investment worth $2,182.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
